International trade is a key driver of growth, jobs and competitiveness for the research-based pharmaceutical sector in Europe. This underpins our industry’s mission to develop life-saving innovative treatments for patients, which is why the pharmaceutical sector strongly supports the CETA agreement. Our high-technology sector is a major asset to both Canada’s and the EU’s economies, where it currently employs nearly 760,000 people.

The innovative pharmaceutical industry is an important player in trade between the EU and Canada and has been a strong supporter of the CETA since the negotiations began in 2009.